Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., . . . Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of clinical oncology, 30(18), 2190. https://doi.org/10.1200/JCO.2011.38.0402
Chicago-Zitierstil (17. Ausg.)Pro, Barbara, et al. "Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-cell Lymphoma: Results of a Phase II Study." Journal of Clinical Oncology 30, no. 18 (2012): 2190. https://doi.org/10.1200/JCO.2011.38.0402.
MLA-Zitierstil (9. Ausg.)Pro, Barbara, et al. "Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-cell Lymphoma: Results of a Phase II Study." Journal of Clinical Oncology, vol. 30, no. 18, 2012, p. 2190, https://doi.org/10.1200/JCO.2011.38.0402.